Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Anakinra may leads to lower WHO Clinical Progression Score of level 7 or above D60 or above compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
It is very uncertain whether anakinra changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
Anakinra showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
Anakinra showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in time to clinical improvement compared with standard care/placebo (low certainty).
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
Fluvoxamine plus standard care showed no clear difference in all‐cause admission to hospital or death (before hospital admission) compared with placebo plus standard care (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether fluvoxamine plus standard care changes serious adverse events (during study period) compared with placebo plus standard care (very low certainty).
It is very uncertain whether fluvoxamine plus standard care changes any adverse events (during study period) compared with placebo plus standard care (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.